Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus by Fátima Cano-Cano, Almudena Lara-Barea, Álvaro Javier Cruz-Gómez, Francisco Martín-Loro, Laura Gómez-Jaramillo, María Carmen González-Montelongo, María Mar Roca-Rodríguez, Lucía Beltrán-Camacho, Lucía Forero, Javier J. González-Rosa, Mª Carmen Durán-Ruiz, Ana I. Arroba, Manuel Aguilar-Diosdado

“…Methods We conducted a proteomic analysis of PBMCs from patients with T1DM and relapsing remitting Multiple Sclerosis (herein forth MS) patients (n = 9 per condition), using a label-free quantitative proteomics approach. The patients were diagnosed following the American Diabetes Association (ADA) criteria for T1DM and McDonald criteria for MS respectively, and were aged over 18 years and more than 2 years from the onset respectively. …”
Get full text

Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer by Haowei Wang, Lei Cheng, Jian Chen, Peixin Chen, Zhuoran Tang, Qianyi Wang, Ying Ma, Chao Zhao, Xuefei Li, Tao Jiang, Fei Zhou, Xiaoxia Chen, Caicun Zhou

“…Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared to evaluate the therapeutic outcomes differences among patients with different oncogenic drivers. …”
Get full text

Bifidobacterium fermentation with infant formulas is associated with benefits for gut and brain barrier function by Emily G. Knox, Paula Sánchez-Díaz, Colin Buttimer, Sarah-Jane Leigh, Klara Vlckova, Colin Hill, Elaine Kennedy, Jonathan O’Regan, Seamus McSweeney, David Goulding, Maria Rodriguez Aburto, Caitriona M. O’Driscoll, John F. Cryan, Eoin Gunnigle, Gerard Clarke

“…Here, we evaluated the impact of four infant formulas fermented with three Bifidobacterium strains, originally isolated from infant stool, on gut and BBB integrity. Cell-free supernatants from these fermentations were exposed to cultures of T84 colonocytes (gut barrier model) or bEnd.3 brain endothelial cells (BBB model), with and without lipopolysaccharide challenge. …”
Get full text

Posterior and Anterior Spinal Fusion for the Management of Deformities in Patients with Parkinson's Disease by Masashi Sato, Takeshi Sainoh, Sumihisa Orita, Kazuyo Yamauchi, Yasuchika Aoki, Tetsuhiro Ishikawa, Masayuki Miyagi, Hiroto Kamoda, Miyako Suzuki, Gou Kubota, Yoshihiro Sakuma, Kazuhide Inage, Yasuhiro Oikawa, Junichi Nakamura, Masashi Takaso, Gen Inoue, Tomoaki Toyone, Kazuhisa Takahashi, Seiji Ohtori

“…The patients became symptom free after surgery. Bony fusion was observed 12 months after surgery. …”
Get full text

Revealing the heterogeneity of treatment resistance in less‐defined subtype diffuse large B cell lymphoma patients by integrating programmed cell death patterns and liquid biopsy by Wei Hua, Jie Liu, Yue Li, Hua Yin, Hao‐Rui Shen, Jia‐Zhu Wu, Yi‐Lin Kong, Bi‐Hui Pan, Jun‐Heng Liang, Li Wang, Jian‐Yong Li, Rui Gao, Jin‐Hua Liang, Wei Xu

“…A potentially effective regimen was speculated for patients with high PCDI scores who tend to exhibit worse progression‐free survival.…”
Get full text

The South African guidelines on enuresis: 2024 update by A Adam, A Badenhorst, F Claassen, T de Maayer, M Fockema, J Fredericks, E Gottlich, J John, N Lala, J Lazarus, S Leahy, H N Lourens, S Maharaj, K M Mathabe, E M Moshokoa, S B A Mutambirwa, K L Petersen, M B Radzuma, A van der Merwe, I van Heerden, C A Zietsman, F Alyami, A Deshpande, G H H Smith

Get full text

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer by Riqing Huang, Anqi Hu, Qixiang Rong, Ditian Shu, Meiting Chen, Wei Yang, Yue Zhang, Qiufan Zheng, Xin An, Cong Xue, Haifeng Li, Yanxia Shi

“…Patients with amplifications in cell cycle-related genes showed inferior median progression-free survival (PFS) than those without amplifications (2.07 months vs. 8.40 months; HR = 5.24; 95% CI 2.11–13.01; p < 0.001), particularly in HER2-low patients (2.07 months vs. 8.27 months; HR = 4.23; 95% CI 1.50–11.91; p = 0.004). …”
Get full text

The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis by Nadiye Sever, Sedat Yıldırım, Ali Fuat Gurbuz, Delyadil Karakaş Kılıç, Esra Zeynelgil, Yunus Emre Altintaş, Berivan Deniz Çimik, Yeşim Ağyol, Ali Kaan Güren, Pınar Erel, Erkam Kocaaslan, Burak Paçacı, Mustafa Alperen Tunç, Abdussamet Çelebi, Nazım Can Demircan, Selver Işık, Rukiye Arıkan, Murat Araz, Serdar Karakaya, Murat Sarı, Osman Köstek, İbrahim Vedat Bayoğlu

“…<i>Results:</i> CAR was identified as an independent prognostic factor for both overall survival (OS) and progression-free survival (PFS). Patients with CAR < 0.98 had significantly longer OS (87.0 months vs. 14.0 months, <i>p</i> < 0.001) and PFS (17.61 months vs. 8.96 months, <i>p</i> = 0.010). …”
Get full text

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review... by Huimin Zhao, Shanshan Huang, Jianyu Wu, Yanlan Lu, Yue Zou, Haijian Zeng, Chunlan Li, Jin Wang, Xiaochen Zhang, Xiaochen Zhang, Siliang Duan, Siliang Duan, Weiming Liang

“…This meta-analysis aimed to assess the efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor (CP) in the treatment of patients with advanced NSCLC.MethodsA systemic search was conducted in four databases (PubMed, Cochrane library, Embase, and Web of Science) from their establishment until January 17, 2024, for randomized controlled trials that investigated the use of the first-line PD-1/PD-L1 inhibitor plus CTLA-4 inhibitor in patients with advanced NSCLC. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were subjected to meta-analyses.ResultsTotally 7 eligible randomized controlled trials including 4682 people were included. …”
Get full text

Sorafenib as Adjuvant Therapy Post–Liver Transplant: A Single-center Experience by Hala Hassanain, MD, Ashton A. Connor, MD, PhD, Elizabeth W. Brombosz, PhD, Khush Patel, MD, MS, Ahmed Elaileh, MD, Tamneet Basra, MD, Sudha Kodali, MD, MSPH, David W. Victor, III, MD, Caroline J. Simon, MD, Yee Lee Cheah, MD, Mark J. Hobeika, MD, Constance M. Mobley, MD, PhD, Ashish Saharia, MD, Sadhna Dhingra, MD, Mary Schwartz, MD, Anaum Maqsood, MD, Kirk Heyne, MD, Ahmed O. Kaseb, MD, Jean-Nicolas Vauthey, MD, A. Osama Gaber, MD, Maen Abdelrahim, MD, PhD, R. Mark Ghobrial, MD, PhD

“…The outcomes were overall survival (OS) and recurrence-free survival (RFS). Adjuvant sorafenib recipients were also propensity score matched 1:2 to nonadjuvant recipients based on recurrence risk features. …”
Get full text

Efficacy and safety of everolimus for patients with focal cortical dysplasia type 2 by Se Hee Kim, Hoon‐Chul Kang, Yun Ho Roh, Jongsung Hahn, Kyung Lok Min, Seok‐Jin Lee, Donghwa Yang, Han Som Choi, Soyoung Park, Jeong Ho Lee, Sang‐Guk Lee, Se Hoon Kim, Min Jung Chang, Heung Dong Kim

“…While the drug was not more effective than a placebo for most, few patients showed better results, with some becoming seizure‐free. Side effects were common but manageable. More research is needed to understand why certain patients respond better to treatment.…”
Get full text

Multiple eco-regions contribute to the seasonal cycle of Antarctic aerosol size distributions by J. Brean, D. C. S. Beddows, E. Asmi, A. Virkkula, A. Virkkula, L. L. J. Quéléver, M. Sipilä, F. Van Den Heuvel, T. Lachlan-Cope, A. Jones, M. Frey, A. Lupi, J. Park, Y. J. Yoon, R. Weller, G. L. Marincovich, G. L. Marincovich, G. C. Mulena, G. C. Mulena, R. M. Harrison, R. M. Harrison, M. Dall'Osto

“…“Aitken high”, “Aitken low” and “bimodal” PNSDs occur 37 %–68 % of the time, most commonly at Dome C on the Antarctic Plateau, and likely arise from atmospheric transport and ageing from aerosol originating likely in both the coastal boundary layer and free troposphere. “Pristine” PNSDs with low aerosol concentrations occur 12 %–45 % of the time, most commonly at Halley, located at low altitudes and far from the coastal melting ice and influenced by air masses from the west. …”
Get full text

The generation and evaluation of TKO/hCD55/hTM/hEPCR gene-modified pigs for clinical organ xenotransplantation by Guoli Huai, Yong Wang, Jiaxiang Du, Zhenhui Cheng, Yuxuan Xie, Jia Zhou, Hongmei Tang, Yanyan Jiang, Xiangyang Xing, Shaoping Deng, Dengke Pan, Dengke Pan, Dengke Pan

“…Furthermore, it is imperative to rear donor pigs in pathogen-free (DPF) facilities to mitigate infection risks and prevent the transmission of porcine pathogens to humans.…”
Get full text

The Effect of Feeding Different Levels of Mineral Biochar on Performance, Blood Parameters, Production and Milk Composition of Holstein Dairy Cows by Ali Khatibi Bardsiri, Reza Valizadeh, Seyed Hadi Ebrahimi, Pirouz Shakeri, Abbas Ali Naserian

“…Introduction: Biochar is a solid product obtained from the thermal conversion of biomass under oxygen-free conditions, which can be used as an additive in animal feed in addition to agricultural applications.The purpose of this study was to use a natural mineral biochar in the diet of Holstein dairy cows and investigate its effect on functional characteristics, blood parameters, milk production and composition.Materials and Methods: This research was conducted using 24 lactating Holstein cows, whose average weight at the beginning of the experiment was 618.25 ± 79.27 kg, average daily milk production was 41.08 ± 3.06 kg, and the number of lactation days was 89.1 ± 19.1 days. …”
Get full text

Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies by Inmaculada Ruiz-Lorente, Lourdes Gimeno, Alicia López-Abad, Pedro López Cubillana, Tomás Fernández Aparicio, Lucas Jesús Asensio Egea, Juan Moreno Avilés, Gloria Doñate Iñiguez, Pablo Luis Guzmán Martínez-Valls, Gerardo Server, Belén Ferri, José Antonio Campillo, María Victoria Martínez-Sánchez, Alfredo Minguela

“…The HLA-B −21M/T genotype was an independent predictive parameter of the progression-free survival (HR = 2.08, <i>p</i> = 0.01) and the OS (HR = 2.059, <i>p</i> = 0.039) of BC patients treated with BCG, together with age and tumor histopathologic characteristics. …”
Get full text

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III... by Roger Owen, John Jones, David Meads, David A Cairns, Christopher Parrish, Gordon Cook, Neil Rabin, Matthew Jenner, Martin Kaiser, Kevin Boyd, Graham Jackson, Catherine Olivier, Amy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Jennifer Bird, Stella Bowcock, Ruth de Tute, Hayley Gardner, Bryony Dawkins, Rowena Henderson, Phillip Best, Bhuvan Kishore, Mark Drayson

“…Following 12 cycles of induction treatment, participants alive and progression free will undergo a second (double-blind) randomisation on a 1:1 basis to maintenance treatment with lenalidomide+placebo versus lenalidomide+ixazomib until disease progression or intolerance.Ethics and dissemination Ethical approval has been obtained from the North East—Tyne &amp; Wear South Research Ethics Committee (19/NE/0125) and capacity and capability confirmed by local research and development departments for each participating centre prior to opening to recruitment. …”
Get full text

Household transmission of SARS-CoV-2 in a rural area in South Africa by G Maimela, C E Martin, M Chersich, B Bello, J Mauti, T Bäernighausen, S Kohler, A Almuedo-Riera, S Luchters, S Sawry

“…We conducted a prospective household cluster investigation between 13 April and 21 July 2021 in the Matjhabeng subdistrict, a rural area in Free State Province, SA. Adults with SARS‐CoV‐2 confirmed by polymerase chain reaction (PCR) tests (index cases, ICs) and their household contacts (HCs) were enrolled. …”
Get full text

Is grip strength linked to body composition and cardiovascular risk markers in primary schoolchildren? Cross-sectional data from three African countries by Juerg Utzinger, Nicole Probst-Hensch, Honorati Masanja, Uwe Pühse, Bassirou Bonfoh, Ivan Müller, Cheryl Walter, Rosa Du Randt, Stefanie Gall, Siphesihle Nqweniso, Peter Steinmann, Markus Gerber, Fredros O Okumu, Serge Ayekoé, Jean T Coulibaly, Dao Daouda, Bomey Clément Gba, Benal Kouassi, Sylvain G Traoré, Marceline F Finda, Elihaika G Minja, Getrud J Mollel, Johanna Beckmann, Christin Lang, Kurt Z Long

“…Inferential statistics are based on mixed linear regressions and analyses of covariance.Results Across all study sites, higher HGS was associated with lower body fat, higher muscle mass and higher fat-free mass (p&lt;0.001, 3.9%–10.0% explained variance), both in boys and girls. …”
Get full text

Enzyme-responsive vitamin D-based micelles for paclitaxel-controlled delivery and synergistic pancreatic cancer therapy by Diana Peixoto, João M. Ravasco, Barbara Blanco-Fernandez, Francisco Veiga, Angel Concheiro, João Conde, Ana Cláudia Paiva-Santos, Carmen Alvarez-Lorenzo

“…PTX-loaded VD3 micelles also exhibited prominent cell internalization and induced a considerable cytotoxic synergistic effect against human PDAC cells (BxPC-3 cells) in 2D and 3D cell culture models compared with free PTX. The PTX-loaded VD3 micelles were hemocompatible and stable after long-term storage in the presence of biorelevant media, and showed higher efficiency to inhibit the tumor growth compared to the approved clinical nanoformulation (Abraxane®) in an in ovo tumor model. …”
Get full text

AICpred: Machine Learning-Based Prediction of Potential Anti-Inflammatory Compounds Targeting TLR4-MyD88 Binding Mechanism by Lucindah N. Fry-Nartey, Cyril Akafia, Ursula S. Nkonu, Spencer B. Baiden, Ignatus Nunana Dorvi, Kwasi Agyenkwa-Mawuli, Odame Agyapong, Claude Fiifi Hayford, Michael D. Wilson, Whelton A. Miller, Samuel K. Kwofie

“…This study introduces AICpred, a robust, free, user-friendly, and easily accessible machine learning-based web application for predicting inhibitors against TLR4 by targeting the TLR4-myeloid differentiation primary response 88 (MyD88) interaction. …”
Get full text